A meta-analysis of 13 randomized trials found that adding immune checkpoint inhibitors did not significantly improve overall survival in unselected patients with advanced ovarian cancer. The analysis reinforces the difficulty of achieving durable survival benefit without patient selection. For clinical and translational teams, the result strengthens the case for better predictive biomarkers and for refining trial design around identifiable responder populations rather than broad maintenance or escalation approaches. —